Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm
21 1월 2009 - 6:52AM
PR Newswire (US)
NEW YORK, Jan. 20 /PRNewswire-FirstCall/ -- Immtech
Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today announced
that the Company has appointed Virchow, Krause & Company, LLP
as its independent registered public accounting firm, effective
immediately. The decision to change the Company's independent
registered public accounting firm was approved by the Company's
board of directors. The appointment will result in cost savings for
Immtech. Virchow Krause is the nation's 17th largest certified
public accounting firm in the United States according to the 2008
Public Accounting Report's "Top 100." About Immtech
Pharmaceuticals, Inc. Immtech Pharmaceuticals, Inc. and
subsidiaries (a development stage enterprise) is focused on global
opportunities in the healthcare sector and opportunities in China.
Immtech aims to leverage its established expertise and other assets
in both new drug sales and enhanced healthcare-related services,
including research and information-providing services, for
developed and developing countries. For additional information,
please visit the Company's website at
http://www.immtechpharma.com/. "Safe Harbor" Statement under the
Private Securities Reform Act of 1995: Statements in this press
release regarding Immtech Pharmaceuticals, Inc.'s business which
are not historical facts, are "forward-looking statements" that
involve risks and uncertainties. Actual results could differ
materially from these forward-looking statements. Factors that
could cause or contribute to such differences include, but are not
limited to, those discussed under the headings "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and "Risk Factors" in Immtech's annual report on Form
10-K for the year ended March 31, 2008 filed on June 18, 2008, and
in its other SEC filings and include, but are not limited to: (i)
conditions in the credit markets and the general economy; (ii)
Immtech's ability to obtain additional funds; (iii) Immtech's
ability to manage its remaining resources; (iv) Immtech's ability
to continue as a going concern; (v) Immtech's ability to retain key
personnel; (vi) the ability of Immtech's scientists and
collaborators to discover new compounds; (vii) the availability of
additional research grants; (viii) Immtech's ability to obtain
regulatory approval of its drug candidates; (ix) the success of
Immtech's clinical trials; (x) dependence upon and contractual
relationship with partners; (xi) Immtech's ability to protect its
intellectual property; and (xii) competition and alternative
technologies. In addition, Immtech does not undertake any
obligation, and specifically disclaims any obligation to publicly
update or revise forward-looking statements to reflect future
events, information or circumstances that arise after the date of
this release. DATASOURCE: Immtech Pharmaceuticals, Inc. CONTACT:
Bill Berry, Berry & Co. for Immtech, +1-212-253-8881 Web Site:
http://www.immtechpharma.com/
Copyright